In this edition of our ongoing series "In The Spotlight", we're excited to chat with Linh Nguyen, the VP Sales at LARVOL. With a passion for healthcare and a commitment to making a difference in the oncology field, Linh has been a vital part of our team for over six years. Let’s get to know Linh better through her own words, exploring her journey, motivations, and the personal interests that round out her life.
I'm Linh Nguyen and I lead the Sales team here at LARVOL. My role is all about building strong relationships with our pharma and biotech customers, ensuring they have the cancer data they need to make informed decisions. It's been a rewarding six years, helping our customers navigate the complexities of oncology data to support their vital work.
My journey into oncology was sparked by a genuine interest in healthcare, especially in understanding and combating cancer. My involvement in a research project on breast cancer during my final year of university deepened my interest in oncology and led me to seek a career where I could blend my passion for healthcare with innovative technology. The opportunity at LARVOL presented itself as a perfect blend of these interests, thanks to connecting online with Bruno, LARVOL's founder.
This role has been the most fulfilling one in my career so far. I find immense joy in solving problems, ensuring everything runs smoothly, and fitting together the pieces of a complex puzzle. Challenges are inevitable, but they're also opportunities for growth and improvement. Overcoming them is a part of the job I genuinely enjoy.
Knowing that our work eventually contributes to improving patient outcomes is a powerful motivator. While we don't interact with patients directly, the thought that our efforts can make a difference in their lives keeps me focused and driven. Additionally, the collective motivation and dedication of my colleagues at LARVOL inspires me to push forward, even when obstacles arise.
Away from the office, I cherish my time with my dog and loved ones. Cooking and baking are my go-to activities for relaxation. They allow me to express creativity and share something tangible and enjoyable with my family and friends.
Through Linh's story, we glimpse the dedication and passion that drive our team at LARVOL. Stay tuned for more inspiring stories from our talented team members in future editions of our "In the Spotlight” series.
79% had reduction in disease. ORR 31%. Many responses deepen over time.
Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.
Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated
Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A
@montypal@cityofhopeoc@CRISPRTX@sitcancer@neerajaiims@DrBenTran@HaanenJohn@DrChoueiri@TiansterZhang@tompowles1@brian_rini@AlbigesL@Uromigos@ERPlimackMD@drenriquegrande@PGrivasMDPhD Congrats Monty! Looking forward to hearing about this exciting first-in the field study!
CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe
Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt
Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7
@montypal you never stop to amaze me! You are brilliant & awesome! Looking forward to hearing more about this trial @sitcancer@OncoAlert@CityofHope_GU@COHMDCareers@neerajaiims@KidneyCancer@KidneyCancerDoc@NazliDizman@ZeynepZengin@LuisMezaco@crisbergerot@PauloBergerott.co/RNzOwxixQm